Myokardia Inc (NASDAQ:MYOK) rose 15.1% on Wednesday . The stock traded as high as $48.00 and last traded at $47.55. Approximately 1,260,000 shares traded hands during mid-day trading, an increase of 88% from the average daily volume of 669,717 shares. The stock had previously closed at $41.30.
MYOK has been the subject of several research analyst reports. TheStreet downgraded shares of Myokardia from a “c” rating to a “d+” rating in a research note on Friday, November 3rd. BidaskClub raised shares of Myokardia from a “sell” rating to a “hold” rating in a research note on Tuesday, December 26th. Zacks Investment Research raised shares of Myokardia from a “sell” rating to a “hold” rating in a research note on Tuesday, October 17th. Wedbush reaffirmed an “outperform” rating and issued a $51.00 price target on shares of Myokardia in a research note on Wednesday, September 20th. Finally, Credit Suisse Group reaffirmed an “outperform” rating and issued a $55.00 price target (up from $45.00) on shares of Myokardia in a research note on Tuesday, September 19th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the company. Myokardia has an average rating of “Hold” and an average price target of $54.83.
The stock has a market cap of $1,730.00 and a P/E ratio of -65.47.
In other news, insider Jake Bauer sold 5,000 shares of the business’s stock in a transaction dated Tuesday, January 9th. The shares were sold at an average price of $45.00, for a total transaction of $225,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Anastasios Gianakakos sold 4,300 shares of the business’s stock in a transaction dated Monday, November 6th. The stock was sold at an average price of $40.23, for a total transaction of $172,989.00. Following the sale, the chief executive officer now directly owns 513,417 shares of the company’s stock, valued at $20,654,765.91. The disclosure for this sale can be found here. Over the last three months, insiders have sold 836,626 shares of company stock valued at $35,146,501. 33.40% of the stock is currently owned by insiders.
Institutional investors have recently added to or reduced their stakes in the stock. Hershey Trust Co. boosted its holdings in Myokardia by 26.0% during the third quarter. Hershey Trust Co. now owns 20,064 shares of the biotechnology company’s stock worth $860,000 after purchasing an additional 4,145 shares during the last quarter. EAM Investors LLC purchased a new position in Myokardia during the third quarter worth about $4,216,000. Northern Trust Corp boosted its holdings in Myokardia by 31.9% during the second quarter. Northern Trust Corp now owns 202,983 shares of the biotechnology company’s stock worth $2,658,000 after purchasing an additional 49,044 shares during the last quarter. Fernwood Investment Management LLC boosted its holdings in Myokardia by 409.1% during the third quarter. Fernwood Investment Management LLC now owns 246,382 shares of the biotechnology company’s stock worth $10,557,000 after purchasing an additional 197,989 shares during the last quarter. Finally, Swiss National Bank boosted its holdings in Myokardia by 25.7% during the second quarter. Swiss National Bank now owns 31,790 shares of the biotechnology company’s stock worth $416,000 after purchasing an additional 6,500 shares during the last quarter. Institutional investors and hedge funds own 63.61% of the company’s stock.
WARNING: “Myokardia (MYOK) Stock Price Up 15.1%” was first posted by Markets Daily and is owned by of Markets Daily. If you are viewing this report on another domain, it was illegally copied and reposted in violation of U.S. & international copyright & trademark legislation. The correct version of this report can be read at https://www.themarketsdaily.com/2018/01/11/myokardia-myok-stock-price-up-15-1.html.
Myokardia Company Profile
MyoKardia, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company is engaged in the business of developing and commercializing therapeutics.
Receive News & Ratings for Myokardia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myokardia and related companies with MarketBeat.com's FREE daily email newsletter.